Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ocular Therapeutix Inc Market Cap
The Ocular Therapeutix Inc (OCUL) share price is expected to increase by 70.84% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered OCUL. Price targets range from $11 at the low end to $22 at the high end. The current analyst consensus for OCUL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
OCUL is a stock in Health Care which has been forecasted to be worth $14.88 as an average. On the higher end, the forecast price is $22 USD by Jonathan Wolleben from JMP Securities and on the lower end OCUL is forecasted to be $11 by Yi Chen from HC Wainwright & Co..
These are the latest 20 analyst ratings of OCUL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Colleen Kusy Baird | Outperform | $17 | Maintains | Aug 8, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 1, 2024 |
| Biren Amin Piper Sandler | Overweight | $15 | Maintains | Jun 21, 2024 |
| Tara Bancroft TD Cowen | Buy | $11 | Upgrade | Jun 20, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $15 | Maintains | Jun 14, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $14 | Reiterates | Jun 14, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $22 | Maintains | May 8, 2024 |
| Tara Bancroft TD Cowen | Hold | $7 | Maintains | May 8, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $14 | Maintains | May 8, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $16 | Reiterates | Apr 19, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $24 | Reiterates | Apr 16, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $15 | Maintains | Mar 13, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $24 | Reiterates | Mar 13, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $24 | Maintains | Mar 12, 2024 |
| Tara Bancroft TD Cowen | Market Perform | $11 | Maintains | Mar 12, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $15 | Maintains | Feb 26, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Feb 14, 2024 |
| Tazeen Ahmad B of A Securities | Buy | $15 | Initiates | Feb 9, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Reiterates | Oct 4, 2023 |
| Colleen Kusy Baird | Outperform | $18 | Reiterates | Sep 14, 2023 |
When did it IPO
2014
Staff Count
267
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Pravin U. Dugel M.D.
Market Cap
$1.40B
In 2023, OCUL generated $58.4M in revenue, which was a increase of 13.49% from the previous year. This can be seen as a signal that OCUL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocular Therapeutix, Inc. (NASDAQ: OCUL) will participate in two investor conferences in September, focusing on its therapies for retinal diseases and eye conditions.
Why It Matters - Ocular Therapeutix's participation in investor conferences could signal upcoming developments or insights into their therapies, potentially impacting stock performance and investor sentiment.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocular Therapeutix, Inc. (NASDAQ: OCUL) will present at four retina meetings in Portugal and Spain in September 2024, focusing on therapies for retinal diseases and eye conditions.
Why It Matters - Ocular Therapeutix's presentations at key retina meetings could signal advancements in their therapies, potentially impacting stock performance and investor sentiment in the biopharmaceutical sector.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Ocular Therapeutix, Inc. (NASDAQ:OCUL) held its Q2 2024 earnings conference call on August 7, 2024, with key executives and analysts participating.
Why It Matters - The earnings call provides insights into Ocular Therapeutix's financial health and future outlook, influencing investor decisions on stock performance and potential investment opportunities.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocular Therapeutix has granted inducement awards to four new employees under its 2019 Stock Incentive Plan, in compliance with Nasdaq regulations.
Why It Matters - Ocular Therapeutix's inducement awards for new hires signal growth and potential expansion, which may lead to increased innovation and value, positively impacting investor sentiment.
Fri, 09 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Ocular Therapeutix (OCUL) has a consensus price target indicating an 85.4% upside potential, supported by an upward trend in earnings estimate revisions.
Why It Matters - The 85.4% upside potential suggests significant growth opportunity for Ocular Therapeutix (OCUL), while rising earnings estimates indicate positive momentum, possibly boosting stock performance.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ocular Therapeutix (NASDAQ: OCUL) reports FDA acceptance of its AXPAXLI™ trial for wet AMD. Cash balance is $459.7M, funding operations into 2028. Q2 2024 results to be discussed in a call today.
Why It Matters - FDA acceptance of the AXPAXLI™ trial is a positive signal for Ocular's product pipeline, potentially leading to future revenue. Strong cash reserves indicate financial stability and operational longevity.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
